Impact of renal function of XXXX with advanced @entity5 on eligibility for first-line chemotherapy and treatment outcomes.

@entity1 @entity632 @entity902 @entity5 @entity3003 @entity1009 @entity900 @entity1259 @entity1499 @entity136 @entity5713
OBJECTIVE: The aim of the study is to clarify the clinical effects of first-line chemotherapy regimens for advanced @entity5 on clinical responses and survival of @entity1 grouped by renal function. METHODS: In this multicenter retrospective cohort study, 345 @entity5 @entity1 received systemic chemotherapy for metastatic or unresectable disease in 17 centers (2004-10). RESULTS: Two hundred and forty-one @entity1 were treated with @entity1499 , @entity5713 , @entity632 and @entity900 / @entity1499 , @entity1259 and @entity900 (n = 136) or @entity136 and @entity900 (n = 105) followed by @entity3003 -based treatments, non- @entity902 treatments or other regimens. After 2008, @entity136 and @entity900 was the most frequently used regimen in @entity1 with an estimated glomerular filtration rate <60 ml/ @entity1009 .73 m(2) and in those with estimated glomerular filtration rate >= 60 ml/ @entity1009 .73 m(2). The @entity136 and @entity900 @entity1 ' complete response rate was 10.5% and their response rate was 52.4%, which was highest among all regimens. @entity136 and @entity900 demonstrated a better 3-year overall survival when the estimated glomerular filtration rate was >= 60 ml/ @entity1009 .73 m(2) (31.4%), but it tended to be worse when the estimated glomerular filtration rate was <60 ml/ @entity1009 .73 m(2) (14.1%). In the latter cases, the dose reduction rate of @entity136 and @entity900 was high (43.9%). Among the @entity1 with estimated glomerular filtration rate <60 ml/ @entity1009 .73 m(2), the 1-year overall survival of the @entity1 treated with a reduced dose of @entity136 and @entity900 was significantly lower than that of those treated with standard-dose @entity136 and @entity900 (26.2 vs. 60.3%, respectively, P = 0.0108). CONCLUSIONS: @entity136 and @entity900 provided favorable responses and survival in @entity1 with estimated glomerular filtration rate >= 60 ml/ @entity1009 .73 m(2) but unsatisfactory oncological outcomes in @entity1 with estimated glomerular filtration rate <60 ml/ @entity1009 .73 m(2), especially when treated with a reduced dose. Alternative regimens might be optimal rather than reduced-dose @entity136 and @entity900 in @entity1 with estimated glomerular filtration rate <60 ml/ @entity1009 .73 m(2).
